Intervention

JAB-21822

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 3 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials3

Recruiting2

Common conditions8

Lead sponsors shown1

Clinical trials

3 shown

JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C MutationNCT06416410 · 2024-08-07

RECRUITING

Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C MutationNCT05288205 · 2022-04-14

RECRUITING

A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in ChinaNCT05009329 · 2021-07-26

ACTIVE_NOT_RECRUITING

Common conditions

Advanced Non-squamous Non-small-cell Lung Cancer1 Colorectal Cancer1 KRAS P.G12C1 Metastatic Non-squamous Non Small Cell Lung Cancer1 Non-small Cell Lung Cancer1 NSCLC1 Pancreatic Ductal Carcinoma1 Solid Tumor1

Leading sponsors

Allist Pharmaceuticals, Inc. 3

Trial status mix

RECRUITING2

ACTIVE_NOT_RECRUITING1

Phase mix

PHASE12

PHASE22

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.